Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma

Modern Pathology

Volumn 27, Issue 1, 2014, Pages 55-61

  Kang, Yuna ^a   Pekmezci, Melike ^a   Folpe, Andrew L ^b   Ersen, Ayca ^b   Horvai, Andrew E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

malignant peripheral nerve sheath tumor; SOX10; synovial sarcoma

Indexed keywords

TRANSCRIPTION FACTOR SOX10;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CYTOGENETICS; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRANEURAL SYNOVIAL SARCOMA; JOINT CANCER; LEG; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MEDICAL HISTORY; MIDDLE AGED; NEURAL CREST; NEUROFIBROMATOSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SCHWANN CELL; SYNOVIAL SARCOMA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CALIFORNIA; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MINNESOTA; NEOPLASM GRADING; NEURILEMMOMA; PREDICTIVE VALUE OF TESTS; SARCOMA, SYNOVIAL; SOXE TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891747948     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.115     Document Type: Article

References (44)

1. Scheithauer BW, Louis DN, Hunter S, et al. Malignant peripheral nerve sheath tumor, In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) World Health Organization Classification of Tumours of the Central Nervous System, 4th edn. IARC Press: Lyon, France, 2007, pp 160-162.
2. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. Mosby: St. Louis, MO, USA, 2008, pp 903-941.
3. Nielsen GP, Antonescu CR, Lothe RA. Malignant peripheral nerve sheath tumor. In: Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone, 4th edn. vol. (IARC Press: Lyons, France. 2013, pp 187-188.
4. Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 2012;123:295-319.
5. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57: 2006-2021. (Pubitemid 16113778)
6. Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci USA 1987;84: 1981-1985. (Pubitemid 17054133)
7. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 2002;133: 1-23. (Pubitemid 34228877)
8. Suurmeijer AJ, De Bruijn DR, Geurts van Kessel A, et al. Synovial sarcoma, In: Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F (eds) WHO Classification of Tumours of Soft Tissue and Bone, 4th edn. IARC Press: Lyon, France, 2013, pp 213-215.
9. Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998;2: 401-421. (Pubitemid 128654510)
10. Guillou L, Kraus M, Dei Tos AP, et al. S-100 protein reactivity in synovial sarcomas-a potentially frequent diagnostic pitfall. Immunohistochemical analysis of 100 cases. Appl Immunohistochem 1997;4:167-175.
11. Daimaru Y, Hashimoto H, EnjojiM.Malignant peripheral nerve-sheath tumors (malignant schwannomas). An immunohistochemical study of 29 cases. Am J Surg Pathol 1985;9:434-444. (Pubitemid 15241143)
12. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008;97:314-320. (Pubitemid 351358579)
13. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009;115:2988-2998.
14. Scheithauer BW, Amrami KK, Folpe AL, et al. Synovial sarcoma of nerve. Hum Pathol 2011;42:568-577.
15. Hruban RH, Shiu MH, Senie RT, et al. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer 1990;66: 1253-1265. (Pubitemid 20310668)
16. Brems H, Beert E, de Ravel T, et al. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009;10:508-515.
17. Turc-Carel C, Dal Cin P, Limon J, et al. In synovial sarcoma. Cancer Genet Cytogenet 1986;23:93.
18. Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001;15:66-78. (Pubitemid 32060683)
19. Kuhlbrodt K, Herbarth B, Sock E, et al. Sox10, a novel transcriptional modulator in glial cells. J Neurosci 1998;18:237-250. (Pubitemid 28046785)
20. Palla B, Su A, Binder S, et al. SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics. Am J Dermatopathol 2013;35:576-581.
21. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-Schwannian and melanocytic marker. Am J Surg Pathol 2008;32:1291-1298.
22. Karamchandani JR, Nielsen TO, van de Rijn M, et al. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol 2012;20:445-450.
23. Cimino-Mathews A, Subhawong AP, Elwood H, et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol 2012;44:959-965.
24. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42: 351-360. (Pubitemid 28502782)
25. Horvai AE, Kramer MJ, O'Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 2006;130: 792-798. (Pubitemid 43886997)
26. Rubin BP, Fletcher CD, Inwards C, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med 2006;130:1616-1629. (Pubitemid 44683789)
27. Adams EJ, Green JA, Clark AH, et al. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999;52:75-77. (Pubitemid 29023513)
28. Horvai AE, DeVries S, Roy R, et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol 2009;22:1477-1488.
29. Hirakawa N, Naka T, Yamamoto I, et al. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol 1996;27:1060-1065. (Pubitemid 26347062)
30. Shimada S, Tsuzuki T, Kuroda M, et al. Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int 2007;57:60-67.
31. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22: 863-872. (Pubitemid 28328232)
32. Foo WC, Cruise MW, Wick MR, et al. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol 2011;135:839-844.
33. Knosel T, Heretsch S, Altendorf-Hofmann A, et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer 2010;46:1170-1176.
34. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 2009;22:872-878.
35. Terry J, Saito T, Subramanian S, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007;31:240-246. (Pubitemid 46175025)
36. O'Sullivan MJ, Kyriakos M, Zhu X, et al. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod Pathol 2000;13:1336-1346. (Pubitemid 32014673)
37. Ladanyi M, Woodruff JM, Scheithauer BW, et al. Re: O'Sullivan MJ, Kyriakos M, Zhu X,Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod pathol 2000;13:1336-46. Mod Pathol 2001;14:733-737.
38. Gubbay J, Collignon J, Koopman P, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990;346: 245-250.
39. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev 1997;7:338-344. (Pubitemid 27292285)
40. Wegner M, Stolt CC. From stem cells to neurons and glia: a Soxist's view of neural development. Trends Neurosci 2005;28:583-588. (Pubitemid 41476688)
41. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999;27:1409-1420. (Pubitemid 29206280)
42. Koopman P, Schepers G, Brenner S, et al. Origin and diversity of the SOX transcription factor gene family: genome-wide analysis in Fugu rubripes. Gene 2004; 328:177-186. (Pubitemid 38352894)
43. Kordes U, Cheng YC, Scotting PJ. Sox group E gene expression distinguishes different types and maturational stages of glial cells in developing chick and mouse. Brain Res Dev Brain Res 2005;157: 209-213. (Pubitemid 40800421)
44. Pytel P, Karrison T, Can G, et al. Neoplasms with Schwannian differentiation express transcription factors known to regulate normal schwann cell development. Int J Surg Pathol 2012;18:449-457.